Scarica l'app Stockscreener
77.86
3.06%
-2.46
Dopo l'orario di chiusura:
77.80
-0.06
-0.08%
Precedente Chiudi:
$80.32
Aprire:
$80.45
Volume 24 ore:
2.28M
Relative Volume:
2.44
Capitalizzazione di mercato:
$3.37B
Reddito:
$2.04M
Utile/perdita netta:
$-162.34M
Rapporto P/E:
-18.93
EPS:
-4.1129
Flusso di cassa netto:
$-129.27M
1 W Prestazione:
+19.42%
1M Prestazione:
+64.26%
6M Prestazione:
+109.53%
1 anno Prestazione:
+265.88%
Intervallo 1D:
$76.22
$82.27
Intervallo di 1 settimana:
$76.07
$88.02
Portata 52W:
$13.37
$88.02
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Nome
Dianthus Therapeutics Inc
Settore
Industria
Telefono
929-999-4055
Indirizzo
7 TIMES SQUARE, NEW YORK
Compare DNTH vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
77.86 | 3.37B | 2.04M | -162.34M | -129.27M | -4.1129 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-10-14 | Iniziato | Truist | Buy |
| 2025-07-02 | Iniziato | William Blair | Outperform |
| 2024-12-20 | Iniziato | TD Cowen | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-26 | Iniziato | Robert W. Baird | Outperform |
| 2024-06-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-16 | Iniziato | H.C. Wainwright | Buy |
| 2024-02-15 | Iniziato | Stifel | Buy |
| 2023-12-26 | Iniziato | Jefferies | Buy |
| 2023-11-22 | Iniziato | Wedbush | Outperform |
| 2023-10-30 | Iniziato | Guggenheim | Buy |
| 2023-09-28 | Iniziato | Raymond James | Outperform |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-06 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-20 | Ripresa | Goldman | Neutral |
| 2021-08-03 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-22 | Reiterato | B. Riley Securities | Buy |
| 2021-06-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-18 | Iniziato | B. Riley Securities | Buy |
| 2021-01-07 | Iniziato | Mizuho | Buy |
| 2020-06-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-03-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-03-15 | Iniziato | Raymond James | Outperform |
Mostra tutto
Dianthus Therapeutics Inc Borsa (DNTH) Ultime notizie
Dianthus Therapeutics launches $400M stock offering - Investing.com Nigeria
Integral Health Asset Management Acquires 150,000 Shares in Dianthus Therapeutics - National Today
Integral Health Asset Management LLC Buys New Stake in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics EVP Sells $2.76M in Stock - National Today
Dianthus therapeutics CAO sells shares for $3.56 million By Investing.com - Investing.com Australia
Insider Selling: Dianthus Therapeutics (NASDAQ:DNTH) CAO Sells 43,682 Shares of Stock - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) CEO Sells 122,918 Shares - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $2,756,468.40 in Stock - MarketBeat
Dianthus therapeutics CEO Garcia sells $10m in shares - Investing.com
Dianthus therapeutics CAO sells shares for $3.56 million - Investing.com India
Dianthus Therapeutics announces proposed $400 million public share offering - MSN
Dianthus Therapeutics EVP Randhawa sells shares for $2.76 million - Investing.com
Dianthus Therapeutics Executives Sell Off Significant Shares - TradingView
Dianthus Therapeutics closes $719M public offering By Investing.com - Investing.com Australia
Assessing Dianthus Therapeutics (DNTH) Valuation After Early CAPTIVATE GO Decision And Premium P/B Multiple - simplywall.st
Dianthus Therapeutics (DNTH) CEO sells 122,918 shares after option exercise - Stock Titan
Dianthus Therapeutics closes $719M public offering - Investing.com South Africa
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision - Yahoo Finance
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Bitget
Biotech Dianthus raises $719M to push autoimmune disease drugs - Stock Titan
Dianthus Therapeutics Launches $81-Per-Share Offering; Net Proceeds Expected at $673.5 Million - TradingView
Dianthus Therapeutics Announces Major Public Equity Offering - TipRanks
Q1 EPS Estimate for Dianthus Therapeutics Reduced by Analyst - MarketBeat
Midtown drug company to sell up to $625M in stock to fund autoimmune research - Crain's New York Business
Dianthus Therapeutics (DNTH) offers 7.31M shares, $624.9M gross - Stock Titan
Best Biotech Stocks To ConsiderMarch 11th - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume After Analyst Upgrade - MarketBeat
Biotech Dianthus prices $625M deal to advance autoimmune drugs - Stock Titan
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - Bitget
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update - MSN
Dianthus Therapeutics says co. prices upsized offering of 7,313,582 shares at $81.00 per share - marketscreener.com
Dianthus Therapeutics Announces Pricing of $625 Million Upsized Public Offering of Common Stock - Quiver Quantitative
Dianthus Therapeutics Says Co. Prices Upsized Offering Of 7,313,582 Shares At $81.00 Per Share - TradingView
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering - GlobeNewswire Inc.
Dianthus Therapeutics’ CAPTIVATE Trial Sparks Renewed Investor Interest - timothysykes.com
Surge in Dianthus Therapeutics Stock Amid Positive Trial Results - StocksToTrade
DNTH Stock Jumps 21.5% Despite Wider-Than-Expected Q4 Loss as Pipeline Prospects Fuel Rally - AlphaStreet
Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating (DNTH) - Seeking Alpha
AutoZone To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Dianthus Therapeutics (NASDAQ:DNTH) Raised to Strong-Buy at Raymond James Financial - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Price Target Raised to $80.00 - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Robert W. Baird Analyst Says - MarketBeat
Guggenheim reiterates buy rating for Dianthus Therapeutics (DNTH) - MSN
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH) - Finviz
Investment firm Raymond James announced an upgrade of biopharmaceutical company Dianthus Therapeutics Inc. (DNTH) stock rating from "Outperform" to "Strong Buy". - Bitget
Beyond the Balance Sheet: What SWOT Reveals About Dianthus Thera - GuruFocus
Raymond James upgrades Dianthus Therapeutics (DNTH) - MSN
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Dianthus Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
AI Integration Exposes Dianthus Therapeutics to Heightened Cyber, Privacy, and Reputational Risks - TipRanks
Dianthus Therapeutics Inc Azioni (DNTH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):